Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA blood product regulations

Executive Summary

Agency is amending regulations to allow alternative methods for licensing, testing, collecting, storing and distributing blood and blood products. Final rule, published in the March 21 Federal Register, also removes the previous requirement that labeling state that a product was nonreactive when tested for hepatitis B surface antigen. The final rule is effective March 21, 1991 and FDA is requesting that manufacturers of products prepared from whole blood submit amended draft labeling before July 19, 1990.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel